Introduction
Worldwide cancer incidence and mortality continues to increase greatly. More than 14.1 million cancer cases and 8.2 million cancer-associated deaths were reported by the latest GLOBOCAN estimates. The burden of cancer has become a serious global problem, particularly in economically developing countries, on account of aging society, smoking, nutritional status, obesity, and physical inactivity. Despite restriction on tobacco use, advocation on vaccination, early diagnosis, and treatment that can prevent cancer mortality effectively, the causes of cancer are still far from clear. 1 According to molecular epidemiological researches, genetic polymorphisms have been implicated in diverse carcinogenesis mechanisms. 2, 3 p53, a tumor suppressor protein, is implicated in almost half of all human cancer. In response of genotoxic stress and oncogenic signals, p53 actives a transcriptional program to induce several cellular damage responses, including apoptosis, cell cycle halt, and autophagy. 4, 5 In certain cases, p53 activity is depressed by the overexpression of MDM2, a cellular antagonist. MDM2 acts as a major node in the P53 pathway. The MDM2 is an ubiquitin ligase E3 for p53, which promotes the degradation of P53 by the proteasome. There is a negative feedback loop between P53 and MDM2, in which activating p53 protein increases MDM2 transcription, and the resulting MDM2 protein interacts with p53, thereby causing p53 degradation.
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Previous reports have clearly shown that polymorphisms associate with diseases susceptibility by altering affected proteins structurally and functionally. Human MDM2 gene is located on chromosome 12q14.3-q15.1, which contains two promoters, an upstream constitutive promoter (P1) and an internal promoter (P2). 7, 8 The genetic variations within either of promoters may alter the expression of MDM2. For instance, MDM2 SNP309 (rs2279744, T.G) within promoter P2 enhances the affinity of promoter with the transcriptional activator SP1 to increase MDM2 transcription, thereby promoting tumor development in the different tissues. 9 In addition, a del1518 polymorphism (rs3730485), a 40 bp insertion/deletion in the MDM2 promoter P1 region, could also affect promoter activity. 10 Recently, several lines of evidence have indicated that the del1518 del-allele contributes to an increase in cancer risk; [11] [12] [13] however, opposite results were also reported. 14, 15 To explore the precise correlation between del1518 polymorphism and cancer risk, we performed this meta-analysis with all eligible publications.
Methods
Publication search
All possible publications related the association between MDM2 del1518 polymorphism and cancer risk were searched for from PubMed and Embase (up to March 29, 2017 ). The following items were used: "MDM2 or mouse double minute 2 homolog or human homolog of mouse double minute 2", "del1518 or rs3730485", "polymorphism or single-nucleotide polymorphism (SNP) or variant", and "tumor or cancer or carcinoma or neoplasm". The reference lists of all eligible studies in the initial search were searched manually to retrieve potentially relevant studies. To broaden our search to find the most relevant research, we also retrieved publications from Chinese Biomedical (CBM) database with items of "MDM2" and "cancer" in Chinese.
inclusion/exclusion criteria
Studies selected had to meet the following inclusion criteria: 1) evaluating the association between MDM2 del1518 polymorphism and cancer risk, 2) case-control studies, 3) supplying detailed genotype distribution data to estimate the odds ratio (OR) with 95% confidence interval (CI), and 4) published in English or Chinese. Only the latest study was selected from duplicate publications. In addition, studies with genotype frequency distribution of controls departed from Hardy-Weinberg equilibrium (HWE) were excluded from the final analysis. Ins/Ins) model. We used the chi square-based Q-test to determine the heterogeneity among studies. A P-value of ,0.1 means significant heterogeneity. Under such circumstances, the random-effects model would be taken to assess the pooled ORs; otherwise, the fixed-effects would be adopted. [16] [17] [18] The quality assessment was also performed using the quality assessment criteria (Table S1 ) as described previously. 19 All studies were scored from 0 to 15, and only studies with a score of $12 were regarded as high quality. Subgroup analysis was conducted by cancer type, source of control, quality score, and race. Begg's funnel plots and Egger's test were used to assess publication bias. The accuracy and reliability of results were verified by sensitivity analysis by sequentially removing one single study at a time to check the influence of deleted study on pooled ORs. All the statistical tests were conducted by STATA Version 11.0 (StataCorp LP, College Station, TX, USA). P,0.05 indicated statistical significance.
Data extraction
Results
study characteristics
As shown in Figure 1 , a total of 14 articles were retrieved from the initial literature search. After careful examination and assessment, three publications were excluded for the 
3775
MDM2 del1518 polymorphism and cancer risk following reasons: one had duplicate data with the previous research 20 and other two were irrelevant with cancer risk. 21, 22 All studies were in agreement with HWE, except for an article by Jin et al. 11 We included this article for the further study because genotype distribution of the TP53 Arg72 Pro polymorphism was in accordance with HWE in the same study. 11 Of these 11 publications, two publications involved two cancer types 14, 23 and one publication involved four cancer types. 24 We divided these articles into different independent studies based on cancer type. And, the controls of these three publications were included into meta-analysis only once. Main characteristics of each study are summarized in Table 1 . Totally, there were 12,905 cases ranging from 132 to 2,501 and 10,026 controls ranging from 132 to 3,749 included in the present meta-analysis. Three studies were conducted on esophageal squamous cell carcinoma, 14, 15, 25 two studies were conducted on breast, 24, 26 colorectal, 11, 24 ovarian cancer, 23, 27 and lung, 24, 28 and five studies were conducted on "others", such as gastric cardiac adenocarcinoma, 14 hepatocellular carcinoma, 12 uterine leiomyoma, 13 prostate cancer, 24 and endometrial cancer. 23 Twelve studies were PB, [11] [12] [13] [14] [24] [25] [26] 28 and four studies were HB. 15, 23, 27 Moreover, there were seven studies performed among Caucasians 13, 23, 24 and nine studies among Asians. 11, 12, 14, 15, [25] [26] [27] [28] In addition, quality scores of seven studies were ,12 and scores of the remaining studies were $12.
Meta-analysis results
The results for the association between del1518 del/ins polymorphism and cancer risk are shown in Table 2 and Figure 2 . 
Publication bias
The publication bias was performed by Begg's funnel plot and Egger's test. We found no asymmetry of funnel plot (Figure 3 ). 
Discussion
The tumor suppressor p53, a transcriptional factor, essentially controls the growth and development of normal cells. 
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hua et al p53 instability may lead to cell cycle disorder and aberrant cellular apoptosis, thereby strongly contributing to malignant transformation and progression. 29, 30 The MDM2 gene, a genomic size of 34 kb, contains two promoters, such as a p53-responsive promoter and a p53-independent promoter. 8 MDM2, as a major mechanism of genetic toxicity and carcinogenesis, is a principle regulator of the stabilization of p53 in the no-stress condition. 31 MDM2, functioning as an E3 ligase, specifically complexes with p53 by the N-terminus domain and induces its degradation through proteasomal pathway. 32, 33 The expression of MDM2 is elevated by p53-positive regulation. Given a negative autoregulatory loop between MDM2 and p53, the importance of MDM2 has been proved in the central part of p53-assosiated signal pathway. 34, 35 Genetic variations, including SNPs and other types of polymorphisms, may modify genetic predisposition to diseases. 36 Some genetic alterations located in the MDM2 gene, such as SN309, 37 have been proved to be associated with cancer risk. 16, 38, 39 As far as we know, there are at least 4,765 polymorphisms found in the MDM2 gene (http://www. ncbi.nlm.nih.gov/projects/SNP). One of the frequently investigated polymorphisms is MDM2 del1518, a common 40 bp Ins/Del polymorphism, located in constitutive promoter with a putative TATA motif. 10, 26 Due to the special location of del1518 polymorphism, its association with cancer risk has been a hot spot. Salimi et al suggested that women carrying del allele had an increased risk of uterine leiomyoma compared with the women carrying MDM2 40 bp insert allele. 13 Jin et al reported that the 40 bp deletion allele had an important role in the oncogenesis of colorectal cancer, specially for rectal cancer. 11 In addition, a genetic association study by Dong et al have found that the del1518 was significantly associated with an increased risk of hepatocellular carcinoma. 12 While some studies have considered del1518 del-allele as susceptibility loci for the risk of various cancer types, 14, 15 other studies failed to confirm its contribution to cancer risk. [23] [24] [25] [26] [27] [28] The discrepant results might be caused by small sample size, and variations among different study populations. Moreover, it is widely believed that malignancies arising from different tissue had completely distinct molecular mechanisms, and even the same cancer type could display significant heterogeneity among different individuals.
In the current meta-analysis, we combined all eligible investigations comprising 12,905 cases and 10,026 controls from 16 studies on MDM2 del1518 polymorphism. We found no significant association between del1518 polymorphism in the overall analysis and stratification analyses by cancer type, ethnicity, source of control, and scores. A latest metaanalysis conducted by Yu et al found that there was no significant difference between del1518 polymorphism and overall squamous cell carcinoma susceptibility with a total of 309 cases and 1,000 controls from three studies, results of which is consistent with the current study. 22 To our knowledge, this investigation is the largest and most comprehensive meta-analysis regarding the association between del1518 polymorphism and all cancer type. However, there were still some limitations to be addressed. First, statistical power might be limited to certain degree, especially for stratified analyses, such as cancer type of gastric, hepatocellular, uterine leiomyoma, prostate, and endometrial. Hence, the results of this meta-analysis should be interpreted with caution. Second, because of the stratification analysis of ethnicity included Asians and Caucasians only, we could not take genetic and geographical differences into consideration. Further analysis should contain diverse area and ethnicities. Third, the results of this study were based on unadjusted estimates by the reason of insufficient data of individual such as age, gender, smoking, environment exposure, and lifestyles. Gene-gene and gene-environment interactions could not be explored. Fourth, there was obvious heterogeneity for the meta-analysis, which might owe to differences in cancer types, the populations, geographical area, and study designs. Finally, the included studies were mainly searched for from PubMed, Embase, and CBM; therefore, publication bias might exist in this metaanalysis for the unavailability of the unpublished studies with negative results.
Conclusion
Our present meta-analysis suggested no association between MDM2 gene del1518 polymorphism and overall cancer susceptibility. Further well-designed study with large sample sizes, different ethnicities, cancer types, and geneenvironment interactions is needed to confirm our findings.
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